| P2093 | author name string | Ather Muneer | |
| P2860 | cites work | Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 |
| | Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study | Q46669710 |
| | Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 |
| | Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies | Q46801835 |
| | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 |
| | Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder | Q46975571 |
| | A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 |
| | An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression | Q47920928 |
| | Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial | Q48082440 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). | Q48247071 |
| | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). | Q48258866 |
| | A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder | Q48266601 |
| | Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors | Q48268298 |
| | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study | Q48310435 |
| | Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms | Q48739416 |
| | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial | Q48793990 |
| | Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. | Q50654265 |
| | Combination treatment with aripiprazole and valproic acid for acute mania: an 8-week, single-blind, randomized controlled trial. | Q50944382 |
| | Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia | Q87558118 |
| | New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine | Q28083061 |
| | Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism | Q28084069 |
| | Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats | Q28546441 |
| | Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice | Q30364693 |
| | The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases | Q33963449 |
| | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 |
| | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis | Q34349641 |
| | Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression | Q34381557 |
| | Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers | Q34544811 |
| | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study | Q34655996 |
| | Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? | Q35012574 |
| | Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update | Q35579215 |
| | Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists | Q36237653 |
| | Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial | Q36664112 |
| | Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder | Q37970762 |
| | Prevalence, chronicity, burden and borders of bipolar disorder | Q38088053 |
| | β-Arrestins in the central nervous system | Q38114220 |
| | Problematic boundaries in the diagnosis of bipolar disorder: the interface with borderline personality disorder | Q38164263 |
| | Suicide in bipolar disorder: a review | Q38218542 |
| | Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study | Q38377712 |
| | Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 |
| | A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies | Q40205139 |
| | A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). | Q42930552 |
| | Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study | Q43080173 |
| | Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study | Q43145175 |
| | Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 |
| | Should the term 'antipsychotic' be changed to 'multidimensional stabiliser' in bipolar disorder? Towards a new denomination for 'atypical antipsychotics'. | Q45045477 |
| | Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode | Q45750933 |
| | Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects | Q46128379 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| | bipolar disorder | Q131755 |
| P304 | page(s) | e562 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Cureus | Q27725810 |
| P1476 | title | The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review | |
| P478 | volume | 8 | |